Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY E CHASTEEN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1427081520
CMS profile
291679
Location
TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,202.56

98 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,202.56 98

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY E CHASTEEN

NPI 1427081520 · CMS profile ID 291679

Allopathic & Osteopathic Physicians / Family Medicine

TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427081520?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY E CHASTEEN, NPI 1427081520, CMS profile ID 291679. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427081520?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JEFFREY E CHASTEEN, NPI 1427081520, CMS profile ID 291679. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427081520?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JEFFREY E CHASTEEN, NPI 1427081520, CMS profile ID 291679, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1427081520?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

98 matching records · $1,202.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 98 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–98 of 98.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kowa Pharmaceuticals America, Inc. $9.9407/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443391 CMS
Merck Sharp & Dohme Corporation $13.4107/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848636527 CMS
Kowa Pharmaceuticals America, Inc. $5.6507/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443385 CMS
Kowa Pharmaceuticals America, Inc. $9.2706/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443381 CMS
Novo Nordisk Inc $10.5306/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811062065 CMS
Daiichi Sankyo Inc. $18.2006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836295633 CMS
Horizon Therapeutics plc $14.6106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797094773 CMS
PFIZER INC. $12.9706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833528623 CMS
Kowa Pharmaceuticals America, Inc. $11.3406/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443377 CMS
Kowa Pharmaceuticals America, Inc. $6.1206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443373 CMS
Kowa Pharmaceuticals America, Inc. $10.4405/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443367 CMS
Novo Nordisk Inc $10.3105/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810944893 CMS
Mylan Specialty L.P. $15.3105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965417271 CMS
Kowa Pharmaceuticals America, Inc. $10.8905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443363 CMS
Daiichi Sankyo Inc. $14.8205/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836288955 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.0905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850324111 CMS
Kowa Pharmaceuticals America, Inc. $11.9605/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443451 CMS
Novo Nordisk Inc $10.9905/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811101465 CMS
Merck Sharp & Dohme Corporation $11.9205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848725391 CMS
Astellas Pharma US Inc $13.2005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821281637 CMS
Kowa Pharmaceuticals America, Inc. $11.4305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443447 CMS
Kowa Pharmaceuticals America, Inc. $11.3904/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443437 CMS
Novo Nordisk Inc $10.4104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811101455 CMS
Kowa Pharmaceuticals America, Inc. $11.4504/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443433 CMS
Amarin Pharma Inc. $13.6504/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815417195 CMS
Kowa Pharmaceuticals America, Inc. $12.1904/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443427 CMS
Novo Nordisk Inc $10.5204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811101449 CMS
Kowa Pharmaceuticals America, Inc. $10.6204/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443395 CMS
Novo Nordisk Inc $5.0104/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811101441 CMS
GlaxoSmithKline, LLC. $25.0004/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803078175 CMS
Kowa Pharmaceuticals America, Inc. $11.0304/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443441 CMS
Novo Nordisk Inc $10.4103/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810864591 CMS
Kowa Pharmaceuticals America, Inc. $6.0203/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443331 CMS
Novo Nordisk Inc $10.3003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811101435 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.2403/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850005731 CMS
Biohaven Pharmaceuticals, Inc. $17.3203/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852456965 CMS
Kowa Pharmaceuticals America, Inc. $12.1103/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443325 CMS
Kowa Pharmaceuticals America, Inc. $13.8202/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443321 CMS
Amgen Inc. $18.1702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825397931 CMS
Kowa Pharmaceuticals America, Inc. $5.8202/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443359 CMS
Kowa Pharmaceuticals America, Inc. $8.8902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443353 CMS
Kowa Pharmaceuticals America, Inc. $11.2002/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443349 CMS
GlaxoSmithKline, LLC. $27.3802/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803055627 CMS
Kowa Pharmaceuticals America, Inc. $11.4601/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443345 CMS
Biohaven Pharmaceuticals, Inc. $13.4001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852456961 CMS
Kowa Pharmaceuticals America, Inc. $12.6601/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443339 CMS
Kowa Pharmaceuticals America, Inc. $9.3401/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443335 CMS
Kowa Pharmaceuticals America, Inc. $8.1801/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805443317 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $679.78 70
PY2020 $699.27 55
PY2021 $1,202.56 98
PY2022 $1,588.63 108
PY2023 $893.71 68
PY2024 $908.33 49
PY2025 $777.38 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $376,443.72 36
PY2024 Recipient $89.51 2
PY2024 Principal investigator $379,561.83 41
PY2023 Recipient $535.01 1
PY2023 Principal investigator $57,477.67 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,144.00 07/28/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422039
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/30/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421974
Principal investigator 1 Janssen Research & Development, LLC $1,972.00 06/30/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422094
Principal investigator 1 Janssen Research & Development, LLC $1,972.00 05/26/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422002
Principal investigator 1 Janssen Research & Development, LLC $2,796.00 04/28/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422062
Principal investigator 1 SANOFI US SERVICES INC. $255.04 04/02/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118763
Principal investigator 1 Janssen Research & Development, LLC $4,778.00 03/24/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422007
Principal investigator 1 Amgen Inc. $3,534.75 03/22/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246641295
Principal investigator 1 SANOFI US SERVICES INC. $1,581.46 03/10/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118752
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 03/10/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118755
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 03/03/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422018
Principal investigator 1 Janssen Research & Development, LLC $6,784.00 03/03/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422057
Principal investigator 1 SANOFI US SERVICES INC. $60.00 02/24/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118760
Principal investigator 1 SANOFI US SERVICES INC. $5,960.00 02/24/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118776
Principal investigator 1 Janssen Research & Development, LLC $169.42 02/21/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421990
Principal investigator 1 SANOFI US SERVICES INC. $240.00 02/18/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118655
Principal investigator 1 SANOFI US SERVICES INC. $3,497.80 02/18/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118734
Principal investigator 1 SANOFI US SERVICES INC. $727.64 02/18/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118738
Principal investigator 1 SANOFI US SERVICES INC. $48.43 02/18/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118747
Principal investigator 1 SANOFI US SERVICES INC. $21.77 02/10/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118767
Principal investigator 1 SANOFI US SERVICES INC. $3,879.00 02/04/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118742
Principal investigator 1 Eli Lilly and Company $731.28 01/31/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187879395
Principal investigator 1 Amgen Inc. $1,995.00 01/29/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246641305
Principal investigator 1 Amgen Inc. $127,501.95 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246641299
Principal investigator 1 Amgen Inc. $54,918.90 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246641303
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421985
Principal investigator 1 Janssen Research & Development, LLC $5,592.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421997
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422013
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422025
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422034
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422049
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/27/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422087
Principal investigator 1 SANOFI US SERVICES INC. $24.97 01/27/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118647
Principal investigator 1 SANOFI US SERVICES INC. $4,576.00 01/13/2025 Non-covered Recipient Entity
Essential Medical Research LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226118772
Principal investigator 1 Celgene Corporation $5,500.00 01/07/2025 Non-covered Recipient Entity
Essential Medical Research, Llc
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222307167
Principal investigator 1 Eli Lilly and Company $123,482.31 01/06/2025 Non-covered Recipient Entity
ESSENTIAL MEDICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187883444